IP Library Granted Patent US 11,932,905
Granted Patent B2
US 11,932,905 · App. 18/185,785 · Granted Mar 19, 2024

Amplification oligonucleotides

Inventors: Ryan Shultzaberger (San Diego, CA); Allen Lipson (San Diego, CA); Daan Witters (San Diego, CA)
Assignee: Singular Genomics Systems, Inc.
C12Q1/6855C12Q1/6874C12Q1/6876
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,932,905
App. No.
18/185,785
Granted
Mar 19, 2024
Kind
B2
Abstract

Disclosed herein, inter alia, are polynucleotides, supports, kits, and methods of use thereof for amplifying, immobilizing, and sequencing polynucleotides.

Claims (28)

1. A plurality of nucleic acid molecules, wherein each nucleic acid molecule comprises a first end, a target sequence, and a second end, wherein the first end comprises SEQ ID NO:92, and wherein each target sequence of said plurality of nucleic acid molecules is different from each other.

2. The plurality of claim 1 , wherein the second end comprises a sequence comprising SEQ ID NO:104, SEQ ID NO:4, SEQ ID NO:102, SEQ ID NO:106, SEQ ID NO:108, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, or SEQ ID NO:140.

3. The plurality of claim 2 , wherein the second end comprises SEQ ID NO:4.

4. The plurality of claim 2 , wherein the second end comprises SEQ ID NO:136.

5. The plurality of claim 1 , wherein the target sequence comprises genomic DNA.

6. The plurality of claim 1 , wherein the target sequence comprises a cancer associated gene, or fragment thereof.

7. The plurality of claim 1 , wherein each nucleic acid molecule comprises 50 to 1000 nucleotides.

8. The plurality of claim 1 , wherein each nucleic acid molecule comprises 100 to 500 nucleotides.

9. The plurality of claim 1 , wherein each nucleic acid molecule consists of 50 to 1000 nucleotides.

10. The plurality of claim 1 , wherein one of said first end or said second end comprise a hairpin adapter.

11. The plurality of claim 1 , wherein said first end and said second end each comprise a hairpin adapter.

12. The plurality of claim 1 , wherein one of said first end or said second end comprise a Y polynucleotide adapter.

13. The plurality of claim 1 , wherein both said first end and said second end comprise a Y polynucleotide adapter.

14. The plurality of claim 1 , wherein said plurality of nucleic acid molecules comprises single-stranded DNA or double-stranded DNA.

15. The plurality of claim 1 , wherein each nucleic acid molecule comprises, from 5′ to 3′, said first end, said target sequence, and said second end.

16. The plurality of claim 1 , wherein the second end comprises SEQ ID NO:104.

17. The plurality of claim 1 , wherein one or more of the nucleic acid molecules are immobilized to a solid support.

18. The plurality of claim 17 , wherein said solid support further comprises one or more complements of said nucleic acid molecules.

19. The plurality of claim 17 , wherein said solid support further comprises a polymer, resist, and/or hydrogel.

20. The plurality of claim 17 , wherein said nucleic acid molecules are covalently attached to a polymer on the solid support via a linker.

21. The plurality of claim 20 , wherein the linker comprises 8 to 16 thymine nucleotides, and wherein the linker is at a 5′ end of the immobilized nucleic acid molecules.

22. The plurality of claim 20 , wherein the linker comprises a cleavable site.

23. The plurality of claim 22 , wherein the cleavable site comprises a deoxyuracil triphosphate (dUTP), diol linker, disulfide linker, photocleavable linker, abasic site, deoxy-8-Oxo-guanine triphosphate (d-8-oxoG), methylated nucleotide, ribonucleotide, or a sequence containing a modified or unmodified nucleotide that is specifically recognized by a cleaving agent.

24. The plurality of claim 17 , wherein said one or more nucleic acid molecules further comprise a first oligonucleotide hybridized to the first end, and wherein said first oligonucleotide is attached to said solid support.

25. The plurality of claim 17 , wherein said one or more nucleic acid molecules further comprise a second oligonucleotide hybridized to the second end, and wherein said second oligonucleotide is attached to said solid support.

26. The plurality of claim 17 , further comprising one or more complements of said nucleic acid molecules immobilized to said solid support.

27. The plurality of claim 26 , wherein said one or more immobilized complements of said nucleic acid molecules are hybridized to said immobilized nucleic acid molecules.

28. The plurality of claim 17 , wherein said one or more immobilized nucleic acid molecules is hybridized to a sequencing primer, and wherein said sequencing primer comprises a labeled nucleotide at a 3′ end.

Assignments (2)
SECURITY INTEREST Recorded Mar 7, 2025
From: SINGULAR GENOMICS SYSTEMS, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 070440/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2023
From: SHULTZABERGER, RYAN; LIPSON, ALLEN; WITTERS, DAAN
To: SINGULAR GENOMICS SYSTEMS, INC
Reel/Frame 063505/0092 →
Continuity (5)
Continuation PCTUS2022075843 · Sep 1, 2022
Provisional Application 63331225 · Apr 14, 2022
Provisional Application 63245414 · Sep 17, 2021
Provisional Application 63240671 · Sep 3, 2021
Related Publication 20230287492A1 · Sep 14, 2023